Keymed Biosciences Inc. revolutionizes ITP treatment with CM313

Keymed Biosciences Inc. has announced a significant breakthrough in the treatment of Immune Thrombocytopenia (ITP) with the introduction of CM313, a novel anti-CD38 monoclonal antibody. Led by Lei Zhang and Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences, the research published in the New England Journal of Medicine showcases the efficacy of this innovative therapy.

The study focused on evaluating CM313's safety and effectiveness in adult patients with primary ITP. Results from the trial involving 22 participants demonstrated remarkable outcomes, with 95.5% of patients achieving a platelet count of ≥50 × 10^9/L within 1 week of treatment initiation. The median response duration was 23 weeks, highlighting the rapid and sustained efficacy of CM313. Moreover, 63.6% of patients maintained a durable sustained platelet count response.

Patients treated with CM313 experienced significant improvements, leading to a reduction in bleeding episodes and the discontinuation of other medications. This therapy not only showed rapid results but also provided long-lasting benefits, offering hope to individuals who have undergone multiple treatments in the past.

CM313, the first domestically-developed anti-CD38 antibody with IND approval in China, has demonstrated favorable safety profiles in previous studies. Keymed Biosciences Inc. remains committed to addressing critical clinical needs by delivering innovative and cost-effective therapies to patients worldwide. Their dedication to efficient drug development ensures a diverse pipeline of antibody-based treatments for various medical conditions.

The groundbreaking study led by Lei Zhang and Renchi Yang's team introduces a promising treatment option for patients with Immune Thrombocytopenia. The rapid and sustained efficacy of CM313 offers hope to individuals seeking effective therapies, marking a significant advancement in the field of hematology.